...
首页> 外文期刊>Thrombosis Research: An International Journal on Vascular Obstruction, Hemorrhage and Hemostasis >The relationship between maintenance dosages of three vitamin K antagonists: acenocoumarol, warfarin and phenprocoumon.
【24h】

The relationship between maintenance dosages of three vitamin K antagonists: acenocoumarol, warfarin and phenprocoumon.

机译:三种维生素K拮抗剂维持剂量的关系:Acenocoumarol,Warfarin和Phenprocoumon。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

INTRODUCTION: Vitamin K antagonists of the coumarin type are widely used oral anticoagulants. OBJECTIVE: We developed a transition algorithm for the maintenance dosages of three frequently used coumarins: warfarin, phenprocoumon and acenocoumarol. METHODS: The study was conducted at the Leiden Anticoagulation Clinic. Patients were participants in a trial of which the main objective was to compare the quality of an oral anticoagulant therapy with phenprocoumon to warfarin. We included patients who initiated oral anticoagulant therapy and patients who were already using acenocoumarol. Patients were randomized to a treatment with warfarin or phenprocoumon. Patients who were randomized to warfarin switched to phenprocoumon at the end of follow-up. We analysed the switch from acenocoumarol to warfarin or phenprocoumon at the start of follow-up and the switch of warfarin to phenprocoumon at the end of follow-up and calculated the transition factors for stable anticoagulation between these three vitamin K antagonists. RESULTS: Fifty-eight patients switched from warfarin to phenprocoumon, 39 from acenocoumarol to phenprocoumon and 44 from acenocoumarol to warfarin. The maintenance dose of warfarin was 0.41 (95%CI 0.39-0.43) times the maintenance dose of phenprocoumon. The transition factor between acenocoumarol and phenprocoumon was 0.84 (95%CI 0.79-0.89) and between acenocoumarol and warfarin 1.85 (95%CI 1.78-1.92). CONCLUSIONS: We determined the transition factors between warfarin, phenprocoumon and acenocoumarol. With these transition factors physicians are able to estimate the maintenance dose when it is necessary for a patient to switch from one coumarin to the other.
机译:简介:香豆素型维生素K拮抗剂是广泛使用的口服抗凝血剂。目的:我们开发了一种用于维持三种经常使用的香豆素的过渡算法:Warfarin,PhenProcoumon和Acenocoumarol。方法:该研究在Leiden抗凝诊所进行。患者是参与者的试验,其中主要目标是将口服抗凝治疗的质量与诸如华法林进行比较。我们包括发起口服抗凝血治疗和已经使用aceNocoumarol的患者的患者。患者随机用Warfarin或Phenprocoumon进行治疗。随机转向华法林的患者在随访结束时切换到菲力口。我们在随访结束时分析了从Acenocoumarol到Warfarin或Phenprocoumon的Warfarin或Phenprocoumon的切换,并计算了这三种维生素K拮抗剂之间稳定抗凝的过渡因子。结果:五十八名患者从华法林切换到菲科科,39来自AceNocoumarol到菲科莫诺和44来自Acenocoumarol到Warfarin。 Warfarin的维持剂量为0.41(95%CI 0.39-0.43)维持剂量的苯处理剂量。 AceNocoumarol和Phenprocoumon之间的过渡因子为0.84(95%CI 0.79-0.89),aceNocoumarol和Warfarin 1.85(95%Ci 1.78-1.92)。结论:我们确定了华法林,诸如苯丙脲和aceNocoumarol之间的过渡因子。随着这些过渡因子,医生能够估计患者需要从一个香豆素切换到另一个人的患者时估计维护剂量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号